Genomic data can be acquired via many methods, including classical cytogenetics, in situ hybridization, and microarray techniques. In addition, data supporting personalized medicine can be obtained by methods that might not be considered ''genomic'' per se, such as immunohistochemical staining. 10 The revolution in genomic medicine, however, has largely been driven by the development of next-generation sequencing (NGS) technologies. Several distinctive characteristics have made NGS a prominent technique in contemporary genomic medicine:
1. The massively parallel nature of NGS allows large amounts of sequence data to be acquired simultaneously and at a low cost per nucleotide. 2. Next-generation sequencing is robust to specimen deficiencies, such as DNA degradation, compared with prior techniques. 11 3. By producing many sequence reads over a given region, NGS is highly sensitive and allows the detection of rare alleles present within a mixed cellular population. 12 4. The cost of NGS testing scales less than linearly with the size of the assay: the costs of sequencing 50 and 500 genes with NGS differ by less than a factor of 10. Therefore, the incremental cost of adding new genes to a gene set is low. 5. Next-generation sequencing lends itself to a wide range of methodologic adaptations that allow variations in the assay size (whole-genome sequencing versus enrichment methods), the analyte detected (DNA versus messenger RNA versus epigenetic changes), and the types of variants that can be detected (single-nucleotide variants, insertions and deletions, copy number variants, and structural variants). In current clinical practice, most NGS cancer testing involves sequencing a panel or set of genes, rather than the entire genome or exome. Sequencing entire genomes or exomes produces a large volume of data without known clinical significance. By focusing on a gene set of interest, a test can achieve greater depth of coverage over regions of interest while minimizing the total amount of sequencing performed. This depth of coverage is particularly critical for cancer testing because of tissue and tumor heterogeneity: somatic variants of interest may be present at a low allele frequency, whereas in most constitutional testing, variants are present at an allele frequency of either 50% or 100%.
Genomic sequencing for cancer care is now offered by commercial for-profit laboratories, independent laboratory networks, and clinical laboratories in academic medical centers and integrated health care networks. There are considerable differences between the tests offered by these early adopters:
1. Some tests are custom-built by the laboratory, while others are based on a vendor-designed kit. 2. Some tests are organ-specific (eg, a panel focusing on lung cancer), while others are relevant to multiple different organs. 3 
The variability among the currently available tests has created a complex environment, which may be confusing to clinicians and pathologists as both users and as developers of NGS cancer testing. Table 1 representing breast cancer genetic mutations and associated Web site, is the product of that working group's efforts.
METHODS
Members of the working group were selected by the chair for their expertise in NGS testing and their knowledge of particular disease genes. The task force included a specialist in each of the major organ systems.
The working group members used their professional knowledge to identify academic pathology departments and reference laboratories offering NGS testing in the fall of 2013. One large community-based practice was included. Each laboratory was queried to determine the genes included in the test or tests offered. These gene lists were posted on some laboratories' Web sites; in other cases, they were provided by laboratory directors. When information was obtained via a Web site, the vendor or organization was contacted to confirm the information's accuracy and timeliness. The gene lists were periodically reconfirmed with the laboratories, and any changes were incorporated (last update May 5, 2014). 
The gene lists offered by these early adopters were compiled into a table (Table 1; and supplemental digital content including  Supplemental Tables 1 and 2 , available for this article at www. archivesofpathology.org in the August 2015 table of contents) without additions or deletions. The genes were then annotated by 1 or more working group members. Specifically, each member reviewed the table to identify genes relevant to his or her assigned organ system. Because a single gene may have different effects in different diseases, the working group created a separate row for each annotated gene-disease pair. The annotation process drew on published knowledge, including public databases and the medical literature. The data elements extracted for each gene-disease pair are listed in Table 2 . Not all elements were abstracted for all genedisease pairs. In addition, genes that were present in only 1 or 2 panels were considered to have insufficient uptake to justify the effort required to annotate them. These are listed in Supplemental May 5, 2014 ; however, the working group recognizes that all the elements of the table will change over time. Inclusion in the CGRL does not represent endorsement of a test by the CAP. In addition, the CGRL is purely descriptive and is not intended to provide consensus or expert opinion regarding the relative value of any given test or gene. The CGRL is not intended to replace the detailed annotations required for test interpretation and/or patient management. The references were derived from a number of sources, including the following CAP Pathology Resource Guides: Genomic Analysis and Molecular Diagnosis, CAP SPECs (Short Presentations in Emerging Concepts) references, and journal articles.
RESULTS
The working group consisted of site-specific experts in cancer genetic sequencing and early adopters of NGS technology. This group identified current NGS-based cancer tests for inclusion in the CGRL (Table 3) .
The gene lists obtained from these laboratories and vendors, accompanied by the annotations produced as described in ''Methods,'' were aggregated into the CGRL (available as Cancer Genomics Resource List 2014). The CGRL can be sorted according to any column. Some users may choose to sort by organ system or tumor type: this view provides a useful reference for those interested primarily in a specific subset of cancers ( Figure 1 ). Sorting by gene is also particularly useful for easily assessing the known significance of a given gene across tumor types. (Figure 2 ). The CGRL includes 611 different genes for which NGS-based mutation testing is offered. Surprisingly, of these 611 genes, 0 genes were listed in every panel, 43 genes were listed in 4 panels, and 54 genes were listed in 3 panels (Figure 3 ). In addition, tests for 393 genes were offered by only 1 or 2 institutions. Mutations in these genes are quite rare. The working group annotated the 218 genes that were included in 3 or more panels and chose not to annotate the remaining genes ( Figure 4 ). 
Breast Cancer
Breast cancer is not a single disease; rather, its molecular and clinical characteristics vary substantially.
14,15 Gene expression profiling has been used to identify early breast cancer cases with such a low risk of recurrence after local therapy and antihormonal therapy that the addition of adjuvant chemotherapy would provide little benefit. 16, 17 The Cancer Genome Atlas (TCGA) recently performed a comprehensive molecular analysis of more than 500 breast cancers; only 3 genes (TP53, PIK3CA, and GATA3) mutated in more than 10% of the tumors were identified. Commonly altered genes included TP53, PIK3CA/PTEN, and RB1; however, the mechanisms of alteration were quite variable and included mutations, deletions, amplifications, and copy number alterations. 18 The Molecular Taxonomy of Breast Cancer International Consortium assessed 2000 cases of breast cancer and identified 10 subgroups with unique gene expression, genomic profiles, and clinical outcomes, demonstrating that the frequency of mutations was variable among the different subgroups. 19, 20 Although these findings are not yet actionable, it is hoped that they will facilitate a more personalized approach to breast cancer in the near future. Table 1 provides a detailed list and the annotation of the genes associated with breast cancer included in the CGRL.
Gastrointestinal-Gastric Cancer
Gastric cancers carry numerous genomic aberrations that result in the development and progression of carcinogenesis. 21, 22 However
A randomized phase 3 clinical trial (ToGA trial) established the utility of targeting HER2/neu in advanced gastric cancer 23 by demonstrating that metastatic gastric or gastroesophageal adenocarcinomas positive for HER2/neu amplification or overexpression showed improved overall survival in trastuzumab-treated subjects. Testing HER2/neu expression and amplification status and adding trastuzumab to the chemotherapy regimen for advanced HER2/neupositive gastric and esophageal cancers has become the standard of care. The overexpression and amplification of HER2/neu has been described in 6% to 35% of gastric and gastroesophageal junction adenocarcinomas.
24,25 HER2/neu amplification in gastric carcinoma is associated with poor outcome [25] [26] [27] and has been shown to be an independent prognostic factor. 24 The CAP reviewed the current guide- Figure 1 . Number of institutions offering gene panels containing from 1 to more than 300 genes. Each bar shows the number of genes that were offered by the stated number of laboratories. lines for the interpretation of HER2/neu expression and amplification. 23, 27, 28 Other promising molecular targets in advanced gastric cancer include the overexpression and amplification of the MET and FGF receptors. MET-and FGFR-targeted therapies are being evaluated in phase 3 trials. MET amplification defines a small (2% of tested cases) but aggressive subset of gastric and esophageal adenocarcinomas, suggesting sensitivity to the targeted MET inhibitor crizotinib. 29 FGFR2 gene amplification, which was detected in 2% of tested gastric tumors, predicts sensitivity to the selective fibroblast growth factor receptor (FGFR) inhibitor AZD4547. 30 In contrast to colorectal cancer, anti-epidermal growth factor receptor (EGFR) therapies (cetuximab, panitumumab, and gefitinib) failed to improve the outcomes of gastric cancer patients in phase 3 trials. 31 In addition, EGFR pathway gene mutations failed to predict resistance to anti-EGFR targeted therapies. 32 
Gastrointestinal-Colorectal Cancer
The most important driver genes of colorectal carcinogenesis have been identified, although the systematic incorporation of this information into a set of clinically useful markers for prognosis or the prediction of susceptibility to therapeutic agents has proven elusive. 33, 34 However, a recent review of mutations identified by the TCGA colorectal cancer study found a high incidence (70%) of cancers with potentially ''druggable'' mutations. 35 The most important mutations linked to known therapeutic benefits in colon cancer were in exons 2, 3, and 4 of KRAS and NRAS. The absence of a KRAS or NRAS mutation implies an intact EGFR-MAPK pathway that is potentially susceptible to anti-EGFR therapy. A therapeutic response generally increases survival by only a few months on average. 36 A BRAF mutation (V600E) in microsatellite-stable colon cancer is associated with a poor outcome but is not a universally accepted predictive marker of anti-EGFR therapy. 37 
Gastrointestinal-Pancreatic Cancer
Numerous genetic alterations are involved in the molecular carcinogenesis of pancreatic adenocarcinoma. Genes that are frequently mutated in pancreatic cancer include KRAS, CDKN2A (p16), TP53, and SMAD4/DPC4. 37 In addition to these key genes, numerous other genetic mutations have been identified that impact various cellular pathways involved in pancreatic carcinogenesis and can potentially serve as theranostic targets. Some of the mutated genes that have been identified in pancreatic cancer and have been added to clinical testing panels include MLL3, TGFBR2, ARID1A, SF3B1, ATM, and ARID2. 38 The GATA4 gene product was found to be overexpressed by immunohistochemical testing of pancreatic ductal adenocarcinoma. 39 Two genes, KLF6 and NFKBIZ, were identified as part of a 6-gene panel used to predict the survival of patients with localized pancreatic ductal adenocarcinoma; both of these genes showed higher expression in the poor prognosis group. 40 Immunohistochemical analyses revealed that elevated tumor expression of the proteins encoded by 2 genes, ERCC1 and RRM1, was associated with poor prognosis 41 ; these genes may serve as potential biomarkers for personalized chemotherapy. Studies of patients with pancreatic cancer treated with gemcitabine have suggested that tumors with high RRM1 expression portended a better prognosis than those with low RRM1 expression, 42 and ovarian cancer studies have suggested that tumors with high ERCC1 expression had a poor response to platinum-based thera- py. 43 Although some of the genes mentioned above appear to have prognostic utility, none of these genes or their protein products are currently useful in the diagnosis of pancreatic adenocarcinoma, nor are they currently approved as theranostic markers.
Intraductal papillary mucinous neoplasms (IPMNs) can give rise to pancreatic adenocarcinoma; however, these cystic lesions are often difficult to diagnose preoperatively. Three genes included in clinical testing panels may be of diagnostic utility. Inactivating mutations in STK11, a tumor suppressor gene, have been identified in IPMNs but not in another known mucinous precursor lesion, pancreatic intraepithelial neoplasia. 44 Activating mutations in PIK3CA, which have been found in a minority of IPMNs, may identify a specific variant called intraductal tubulopapillary neoplasm. 45 Finally, more than 40% of IPMNs harbor mutations in GNAS (and often in KRAS as well), a feature that can be of diagnostic utility in preoperative cyst fluid analyses 46 because other cystic pancreatic lesions do not appear to harbor GNAS mutations. 44 
Genitourinary-Prostate Cancer
Approximately 50% of all primary prostate cancers possess TMPRSS2:ERG rearrangements. 47 Several other ERG rearrangements have been reported in prostate cancer, including rearrangements involving the ETS family members ETV1 (7p21.2) and ETV4 (17q21) as well as the RAF kinase gene. [48] [49] [50] [51] [52] The subsequent overexpression of the ERG protein is virtually 100% specific for the presence of prostate cancer in surgical specimens. 53, 54 SPOP is the most frequently mutated gene in prostate cancer studies, with mutations found in 6% to 15% of cases across multiple independent cohorts. 55, 56 Recurrent genetic alterations in prostate cancer frequently involve genes that mediate AR signaling, common tumor suppressors, and chromatin modification genes. The activation of the PI3K and RAS/ RAF signaling pathways occurs in approximately 42% of prostate cancers.
57 SPINK1 mutations define an aggressive molecular subtype of ETS fusion-negative prostate cancers and account for approximately 10% of all prostate cancers.
58
EZH2 is significantly upregulated in prostate cancer and is associated with cancer aggressiveness. 59 Other genetic alterations associated with prostate cancer include the loss of NKX3.1 and PTEN as well as mutations in AR, AKT1, TP53, RB1, and PIK3CA.
55,57,60,61

Genitourinary-Bladder Cancer
The most important driver mutations of urothelial bladder carcinoma occur in FGFR3 and TP53, which define 2 distinct pathways in urothelial bladder carcinoma.
62 FGFR3 mutations are associated with low-stage, low-grade, superficial papillary tumors with favorable disease characteristics and lower rates of recurrence and progression; TP53 mutations occur in up to 70% of muscle-invasive bladder cancers and are associated with high-stage, high-grade tumors. 63 Carcinoma in situ has a high rate of TP53 mutations, 64 and the following genetic mutation rates have been reported for urothelial carcinoma: PIK3CA, 26%; CDKN2A/B, 23%; RB1, 17%; CCND1, 14%; FGFR1, 14%; CCND3, 11%; FGFR3, 11%; MDM2, 11%; EGFR, 6%; and HER2/neu, 6%. 65 Other genetic alterations have been identified in bladder carcinogenesis, including mutations in RAS gene family members and in TERT, as well as the loss of the RB1 and PTEN tumor suppressors. 63, [66] [67] [68] With the exception of genes such as FGFR3, TP53, RB1, HER2/neu, CDKN2A, VEGF, and PTEN, most of the identified alterations have not been related to outcome or treatment response; thus, their roles require further refinement.
60,63
Gynecologic Cancers
The genetic tests identified by this working group included approximately 40 genes with specific relevance to gynecologic cancers, particularly endometrial and ovarian cancers. Many of these genes have functions in multiple tumor types and sites; for example, the tumor suppressor gene PTEN is commonly mutated in endometrioid cancers of both the endometrium and ovary. Several important genes in gynecologic cancers-for example, PTEN, ARID1A, and HER2/neu-may exhibit somatic mutations in numerous regions of the gene, making a sequencing-based approach more attractive than hotspot testing or single-nucleotide genotyping. Several targeted therapies for gynecologic cancers are either in current use or in advanced stages of development, including tyrosine kinase inhibitors for FGFR2-mutated tumors, PARP inhibitors [69] [70] [71] for tumors with ''BRCAness, '' 72,73 and mTor inhibitors for tumors with mutations in the PI3K/mTor/Akt pathway. [74] [75] [76] Next-generation sequencing testing is therefore positioned to play an important role in therapy selection for cancers of this organ system.
Head and Neck Cancers
Most head and neck cancers are squamous cell carcinomas, which are often associated with human papillomavirus (HPV) infection or with alcohol and tobacco use. 77 Head and neck squamous cell carcinomas (HNSCCs) are heterogeneous tumors with mutational patterns that differ between HPV-positive and HPV-negative tumors. 78 The mutational rate of non-HPV-related HNSCCs is comparable to that of other smoking-related malignancies and is approximately double that of HPV-related HNSCCs. 78 Recently, molecular subtypes of HNSCCs were identified by using expression profiling. 79 Most cases of HNSCC exhibit high EGFR expression due to amplification (approximately 17% of cases) or posttranslational modifications. Genetic alterations in the PIK3/AKT/mTOR pathway, which is downstream of EGFR, are also often identified in HNSCCs (74% of cases).
80
PIK3CA is of particular interest because inhibitors are already under development for breast cancer treatment. Several salivary gland neoplasms and HNSCCs are associated with translocations, including MECT1/MAML t(11;19) in mucoepidermoid carcinoma, MYB/NFIB t(6;9) in adenoid cystic carcinoma, ETV6/NTRK3 t(12;15) in mammary analog secretory carcinoma, and EWSR/ATF1 t(12;22) in clear cell carcinoma. As research in the role of genetic translocations in head and neck cancers continues to develop, additional significant genes are likely to be identified.
Head and Neck-Thyroid Cancer
Thyroid cancer is the most common malignancy of endocrine organs, and its incidence is increasing steadily in the United States and worldwide. It is clinically important to establish a thyroid cancer diagnosis preoperatively and to separate thyroid nodules that are malignant and need to be surgically removed from benign nodules that do not require surgery. It is also important to predict aggressive behavior of well-differentiated thyroid cancers and to select appropriate therapies for dedifferentiated tumors. Performing NGS of genes involved in thyroid carcinogenesis can address these challenges. 81 The most common mutations in papillary thyroid cancer (PTC) are point mutations of the BRAF and RAS genes and rearrangements of RET/PTC, NTRK1, and NTRK3 (a recent discovery), all of which are able to activate the mitogen-activated protein kinase (MAPK) pathway. These mutations are found in more than 70% of PTCs.
81-85
RAS mutations and PAX8/PPARGc rearrangements, which are also mutually exclusive, have been identified in 70% to 75% of follicular thyroid carcinomas. 81, 86 Genetic alterations involving the PI3K/AKT signaling pathway have also been observed in thyroid tumors, particularly in advanced and dedifferentiated tumors. 81, [87] [88] [89] Additional mutations known to occur in poorly differentiated and anaplastic carcinomas involve the TP53, AKT1, and CTNNB1 genes. Medullary thyroid carcinomas, both familial and sporadic, frequently carry point mutations in the RET and RAS genes. 81, 90, 91 All of these genetic alterations are helpful for establishing a diagnosis of malignancy in thyroid fine-needle aspiration (FNA) samples. 81 In addition, mutations in some genes (eg, BRAF and TERT) are associated with a more aggressive tumor phenotype and can be used as prognostic markers. 92, 93 Finally, a number of known (BRAF, RET) and recently discovered (STRN-ALK) mutational markers may guide the selection of targeted therapies for aggressive types of thyroid cancer. 94 
Hematologic Malignancies
Many clinically relevant and disease-dependent alterations in hematologic malignancies are translocations. In acute myeloid leukemias and myeloproliferative neoplasms, the presence of a specific translocation determines malignancy and is used to identify the category and subtype of leukemia, as outlined by the World Health Organization Classification of Tumours. 95 For example, a translocation such as the Philadelphia chromosome, t(9;22)(q34;q11), which involves the BCR and ABL genes, is required for diagnosis of chronic myelogenous leukemia. In addition to diagnostic information, identifying the BCR/ABL translocation provides important information about the patient's prognosis and response to the ABL kinase-specific drug imatinib. A diagnosis of acute promyelocytic leukemia requires the identification of the t(15;17)(q24:q12); PML/RARA rearrangement or related rearrangements. The response to trans retinoic acid and anthracycline depends on which specific translocation is present. The clinically relevant translocations involved in all the subtypes of myeloid neoplasms are too numerous to describe here.
Myeloid malignancies are also associated with many prognostically and therapeutically important inactivating and activating mutations, short deletions, and duplications that affect the clinical course and can be identified by using NGS. These include alterations in FLT3, NPM1, CEBPA, c-KIT, IDH1, IDH2, TET2, MLL, DNMT3A, JAK2, RUNX1, and many more. 96 Translocations are a diagnostic and prognostic feature of many lymphoid malignancies of mature and immature T and B cells. Translocations involving the immunoglobulin heavy-chain or j or k light-chain genes, on chromosome 14, 2, and 22, respectively, are observed in B-cell malignancies. Furthermore, translocations involving the T-cell receptor a, b, k, or d genes, on chromosomes 14(q11), 7(q35-6), 7(p15), and 14(q11), respectively, are observed in T-cell malignancies. The translocation partners are extremely varied and are either diagnostic or prognostic in many cases. Many other partners are classically found in B-cell and T-cell malignancies. The hallmark translocations t(8;14)(q24;32), t(14;16)(q32;q21), and t(11;14)(q13;32) are associated with Burkitt lymphoma, follicular lymphoma, and mantle cell lymphoma, respectively. Single-nucleotide variants are not commonly found in malignant lymphomas. 95, 97 Translocations are frequently used as diagnostic and prognostic markers for different subtypes of precursor B and T lymphoblastic leukemia/lymphoblastic lymphoma. The following translocations are observed in precursor B lymphoblastic leukemia/lymphoma: t(12;21)(p13;q22) involving TEL/AML1 (16%-29% of cases), t(1;19)(q23;p13.3) involving PBX/E2A (6% of cases), t(4;11)(q21;q23) involving AF4/MLL (2%-3% of cases), and t(9;22)(q34;q11.2) involving BCR/ABL (3%-4% of cases). Each translocation confers a different clinical phenotype and prognosis, and clinical decisions are influenced by the identification of these specific abnormalities. Mutations in CRLF2, IKZL1, TP53, ERG, and NOTCH have also been detected in precursor B and T lymphoblastic leukemia/lymphoblastic lymphoma and confer an adverse prognosis. 96, 97 Many additional translocations have been identified in patients with T lymphoblastic leukemia/lymphomas, but these have not been linked to diagnostic subtype, prognosis, or therapy as abnormalities in precursor B lymphoblastic leukemia/lymphoblastic lymphoma have.
In contrast to lymphomas, mature B-cell lymphoid malignancies, chronic lymphocytic leukemia (CLL), and hairy cell leukemia are associated with characteristic deletions, insertions, chromosome duplications, and mutations, which define disease progression and clinical prognosis. The most common aberrations in CLL include 13q deletion, trisomy 12, and deletions of 11q, 17p, or 6q. Many other genes are commonly mutated in CLL, including the following: NOTCH1; XPO1 (exportin 1); MYD88; KLH6 (Kelch-like 6); TP53; TGM; BIRC3; PLEKHG5; ATM; SF3B1 (splicing factor 3, B1 unit); ZMYM3; MAPK1; FBXW7; and DDX3X. Mutations in these genes often confer a worse prognosis.
98-100
The identification of the BRAF V600E mutation in almost 100% of hairy cell leukemia cases has refined the diagnosis, prognosis, and therapeutic strategies for this disease. 101 This mutation is found only rarely in multiple myeloma or other B-cell malignancies.
Lung Cancer
Lung adenocarcinoma is one of the highest profile cancers for which NGS is beneficial. Several critical, mutually exclusive ''driver'' oncogenes have been found to render some lung cancers susceptible to treatment with specific targeted inhibitors. The first discovered and largest (~20%) group of lung adenocarcinomas carry mutations in exons 18 to 21 of EGFR. Among these tumors, approximately 80% respond radiographically to treatment with targeted inhibitors of the EGFR tyrosine kinase domain (TKIs), such as gefitinib or erlotinib, with a resulting increase in progression-free survival in advanced-stage lung cancer from approximately 6 months to approximately 15 months. However, these patients inevitably relapse, often with either a secondary mutation in EGFR exon 20 or with a copy number gain of the MET oncogene, although other mechanisms have been reported. Following the discovery of EGFR, similar responses were reported for tumors that contained ALK (~5%) or ROS1 (~1%) rearrangements and were treated with an ALK TKI. Other small subsets of patients with lung adenocarcinomas have been reported to bear rearrangements of RET, NTRK1, or FGFR1/2/3, or mutations involving HER2/neu, BRAF, or PIK3CA; each of these populations is currently being studied for its response to specific targeted inhibitors, with promising preliminary results.
By contrast, less is known concerning squamous cell or small cell carcinomas of the lung. These cancers do not appear to contain the same alterations or exhibit the same responses to targeted therapies as adenocarcinomas. There have been recent reports of squamous cell carcinomas of the lung bearing several recurrent alterations, including copy number gains or, less commonly, mutations in the FGFR genes and in DDR2. Case reports of responses to targeted inhibitors have been published, and clinical trials are ongoing.
Melanoma
Melanoma can be divided into multiple genetic subsets by mutations that are generally mutually exclusive. The BRAF V600 mutation in exon 15 is present in up to half of cutaneous melanoma cases, which can be treated with US Food and Drug Administration-approved inhibitors, [102] [103] [104] [105] [106] for which clinical trials are underway to determine the best therapy. [107] [108] [109] Both NRAS and BRAF mutations may also carry prognostic significance. [110] [111] [112] [113] Another subset of melanoma cases exhibit a loss of NF1, which encodes a RAS-GTPase (guanosine triphosphatase)-activating protein that normally inactivates the wild-type RAS protein; the loss of NF1 increases the activation of pathways downstream of RAS. 114, 115 Up to 20% of mucosal and acral lentiginous melanomas, which are very rare compared with cutaneous cases, possess activating mutations and/or amplification of the KIT locus on 4q12. 116, 117 Such cases can be treated with the appropriate tyrosine kinase inhibitors. 118 Because KIT, NRAS, and NF1 mutations in melanomas tend to activate both the ERK and AKT pathways to some degree, these mutations are generally mutually exclusive. 114, 119, 120 BRAF mutations primarily activate the ERK pathway, but a complementary loss of PTEN or other events can concomitantly activate AKT in these tumors. 108 One-third of cutaneous melanomas lack mutations in any of these genes, but many show a variety of genetic events that activate the ERK and AKT pathways. Uveal melanomas adopt an alternative genetic route, with activating mutations in GNAQ and GNA11, which encode a subunits of heterotrimeric G proteins that activate phospholipase signaling pathways. 121, 122 Melanomas commonly contain mutations in other genes, such as CDKN2A, TP53, and other, more novel genes; however, no targeted therapies have been developed for such cases. 114, 119, 120, 123 Multiplex genetic testing approaches are increasingly used to assign patients to the targeted therapy approaches that are best suited to their specific mutations. Mutational profiles may also facilitate the selection of immune activation treatments, which show great promise in melanoma. [124] [125] [126] Nervous System Tumors Although there are a wide range of central nervous system tumors, genetic changes are particularly relevant in neuroblastomas and gliomas. MYCN amplification is a wellknown genetic abnormality in neuroblastoma, but somatic mutations are found in only a small number of tumors. 127, 128 ALK mutations are the most common somatic mutation in neuroblastoma and represent a potential therapeutic target. In low-grade gliomas, the most relevant genetic changes are the codeletion of 1p and 19q and IDH1 mutations, both of which are associated with a better prognosis and the oligodendroglial phenotype.
129 Numerous genetic changes have been found in glioblastoma multiforme (GBM). Many of these changes are not unique to GBM but are common in other cancers (PTEN, P53, EGFR, PDGFRA, and PIK3CA); others, such as TERT mutations and MGMT promoter methylation, are more specific to GBM. 130 MGMT promoter methylation leads to the silencing of MGMT and predicts treatment response and prognosis. 131 
Sarcomas
Sarcomas, whether occurring in soft tissues, the gastrointestinal tract, reproductive organs, or elsewhere, are associated with translocations that produce functional fusion genes. 132 Although the presence of a particular translocation is not an absolutely sensitive or specific indicator of a given diagnosis, a limited set of translocations is characteristic of many sarcomas. Consequently, testing for chromosomal rearrangements has been incorporated into sarcoma treatment guidelines. 133 Unfortunately, it is difficult to identify translocations by using chromosomal DNA sequence analyses (either traditional Sanger methods or NGS approaches) because the breakpoints that produce the rearrangements occur within different introns of the involved genes in regions that are at least several kilobases long. 134 Consequently, interphase fluorescence in situ hybridization or reverse transcriptase-polymerase chain reaction are the laboratory methods most commonly used to detect translocations. However, NGS methods can be used to identify translocations with the appropriate ''wetlab'' assay design and bioinformatic analysis, most commonly using a hybrid capture approach. 135, 136 The development of targeted therapies directed against specific proteins in the intracellular cascades activated by the fusion geneencoded chimeric proteins has promoted interest in testing for characteristic translocations in sarcomas to guide therapy rather than merely to guide diagnosis.
In addition, single-nucleotide variants (eg, inactivating mutations in hSNF5/INI1) and short indels (eg, short inframe deletions in KIT) are increasingly recognized as characteristic of other sarcoma types. In contrast with translocations, these mutation types can readily be identified by using both NGS approaches and traditional sequencing methods. For some tumor types (eg, gastrointestinal stromal tumors), specific mutations are correlated with the response to particular therapeutic agents. 137 Furthermore, because the mutations that allow some tumors to escape primary therapy have been categorized, it is sometimes possible to use targeted therapy even in the context of recurrent disease. 137 
COMMENT
The goal of developing this comprehensive list of cancer gene panels offered by early NGS adopters was to assist the laboratory pathology communities. The main audience to which our effort was targeted included the current and next waves of pathologist adopters of targeted large panels for cancer, based on the NGS platform. This list will provide the greatest benefits for academic and large reference laboratories, although large pathology groups and hospital systems will also benefit. The rapid availability of the list will assist in the development of laboratory-developed tests for individual use. Pathologists could design a gene panel by using the data included in the CAP cancer resource list and adding other genes specific to the interest of their institution. Forprofit reference laboratories can use the panel to develop in vitro diagnostic medical device kits, and pharmaceutical companies can use it to develop clinical trials. Finally, both hematologists/oncologists and patients might find the list useful. Therefore, the resource list is expected to benefit current pathology adopters, the next wave of pathology adopters, and all the members of the pathology and molecular diagnostic communities, including providers and patients.
Multigene NGS tests have been described by using various terms, including gene set and panel. The term panel has been criticized by payers and regulators owing to concerns related to test bundling. When clinicians can order multiple separate tests by checking a single box, they may become desensitized to the cost of the individual tests or to the possibility of ordering less than the full panel. 138 Indeed, anecdotal evidence indicates that payers have refused to approve NGS panels on the grounds that they represent unnecessary test bundling. However, we submit that the term panel has a special meaning in the NGS context. Instead of representing a grouping of multiple individually orderable tests, a multigene NGS panel represents a single test that encompasses multiple genomic regions. Most critically, eliminating individual genes from an NGS panel does not significantly reduce the cost of the assay. The blanket rejection of these tests on the semantic grounds that they represent ''panels'' obscures real questions that remain about the optimal design of these tests. We therefore propose the re-adoption of panel as a valid and useful term to describe multigene NGS assays.
In selecting genes for inclusion in clinical genomics assays, some laboratories have chosen to create diseasespecific gene sets (eg, ''lung genes'' for lung cancer), while others have designed a single ''pan-cancer'' test appropriate for all cancer types. Each of these approaches has advantages and disadvantages.
Among the laboratories surveyed by the CGRL Working Group, Knight Diagnostic Laboratories at Oregon Health and Science University (Portland) 139 exemplifies the diseasespecific approach; this laboratory offers a specific NGS test for non-small cell lung cancer, another for gastrointestinal stromal tumors, and another for leukemia. Similarly, the University of Pittsburgh Medical Center (Pittsburgh, Pennsylvania) has developed a specific panel for the preoperative diagnosis of thyroid cancer. 81 Ambry Genetics has also created a series of cancer site-specific NGS tests, 140 although these tests are designed to detect constitutional cancer predisposition variants. The disease-specific approach has the advantage of reducing the size of the assay, potentially allowing higher throughput through greater sample multiplexing. The identified variants in a focused gene set are relatively more likely to have been discussed in the literature in the context of the patient's tumor type; that is, the significance of identified variants is more likely to be known. Focused gene sets also reduce exposure to incidental variants.
Pan-cancer tests have also been implemented in several of the laboratories we surveyed, including Washington University (St Louis, Missouri) 141 and Foundation Medicine (Cambridge, Massachusetts).
142 These tests include a larger group of genes, all of which are associated with actionable variants in some tumor type. Arguments in favor of this approach include simplified development; a single assay need only be validated once, whereas multiple diseasespecific assays require multiple validation procedures. The laboratory workflow is also simpler with a pan-cancer test than with multiple site-specific tests. More importantly, by sequencing genes that are not canonically mutated in the patient's cancer type, one increases the probability of discovering unexpected variants. Indeed, the promise of precision medicine is that the mutational profile of a patient's tumor may be more important than the tumor's site of origin or direction of differentiation. 143 Because the cost of testing is an important consideration, it is noteworthy that the cost of NGS-based assays does not scale directly with the number of genes tested; the costs of sequencing targeted sets of 15 or 50 genes are similar. Thus, the difference in assay size between disease-specific tests and pan-cancer tests is not accompanied by a proportionate increase in cost.
A detailed description of the strategies for validating NGS panel tests is beyond the scope of this article, but several general points are worth mentioning. First, NGS panel tests are fundamentally similar to every other laboratory test and thus require a formal analysis of factors such as their sensitivity, specificity, reproducibility, and reference range. Second, NGS panel tests involve 2 separate components: a wet-lab component (for DNA extraction, library preparation, and actual sequence generation) and an in silico component (the bioinformatic process by which variants are identified and annotated), both of which require formal validation. [144] [145] [146] [147] Third, several regulatory agencies have promulgated requirements for validation, and it is clear that different validation approaches fulfill these requirements. 141, 142, 148 Available gene panels for NGS may be either predesigned by the manufacturers of sequencing platforms or designed by individual users. Predesigned gene panels are easier and faster to validate and implement in a clinical laboratory because the manufacturer performs the initial troubleshooting and library optimization, provides stepby-step instructions for the sequencing process, and frequently supplies the analytic pipeline for data interpretation. However, the library design, gene selection, and bioinformatics pipeline are ''locked'' by the manufacturer. By contrast, custom gene panels allow flexibility in choosing an optimal methodologic approach (eg, hybrid capture versus amplification-based sequencing) and in selecting an appropriate sequencing platform. Custom panels allow the inclusion of a variable number of genes (targets) of interest according to the goals of the panel, and they allow the user to modify the panel as new targets become available. The development and validation of a custom panel can be tedious and time consuming. This process begins with reviews of the PubMed (US National Library of Medicine, Bethesda, Maryland) literature and various mutation databases to identify the genes, exons, or hotspots of interest. The genomic coordinates for these alterations must be submitted to a manufacturer for the synthesis of primers for a target amplification-based library or for hybrid capture probes. Next, extensive troubleshooting of the panel's accuracy and performance characteristics (such as depth and uniformity of coverage and reads on target) is performed; suboptimal results might require the redesign of the entire panel. Finally, more extensive validation is required for custom gene panels, including validation of the ''wet'' sequencing part and the custom bioinformatics pipeline.
The greatest challenge associated with performing NGS tests is the clinical interpretation of the results. For most tested genes, there is a finite and relatively small number of variants with well-established clinical significance (eg, the BRAF V600E mutation in melanoma and the EGFR L858R mutation in lung adenocarcinoma). When performing NGS of cancer samples, particularly when a matched constitutional sample is not available, these few, well-established mutations represent a small percentage of the alterations detected by the analysis. Most of the discovered mutations are of unclear significance, presenting the reporting laboratory with a conundrum: how much effort should be invested in analyzing the importance of each of these mutations?
Numerous informatics tools are available to assist with these interpretations: published literature searches, databases of mutations reported previously in cancer or in constitutional samples from healthy volunteers, in silico functional prediction tools that analyze the likely functional and structural consequences of the amino acid changes encoded by the mutation, and assessments of the conservation of a given nucleotide through evolution. Ultimately, however, none of these tools are sufficient for a definitive assessment. The laboratory quality health care provider issuing the report must synthesize this information and render a personal, professional opinion. An automated knowledge base can store these interpretations so that the next time a gene mutation-disease pair is encountered, time is saved; nonetheless, the effort required for the initial interpretations is significant.
An alternative is to interpret only the mutations that have a well-established meaning and to present the remainder as a list of variants of uncertain significance. This approach places the onus for interpreting these results on the practitioner who receives the report, who may not be well equipped to perform this function within the time constraints of a clinical practice. If the practitioner cannot interpret the variants of uncertain significance or explain their meaning to patients, some patients will undoubtedly attempt to interpret them themselves, relying heavily upon Web-based resources.
One potential solution would be a shared knowledge base, similar to the existing databases that catalog the presence of mutations in various genes in various tumors. In this instance, however, the functional relevance of these mutations would be included. Currently, each institution performing NGS is compiling its own private knowledge base, leading to parallelized efforts. A coordinated, cooperative effort would be more efficient in the long run. This problem will only be magnified exponentially when technology advances from panels of a few hundred genes to the entire exome and genome.
In summary, the PHC Committee of the CAP developed a cancer genomics resource list to assist the laboratory pathology and clinical oncology communities. The CGRL provides a table listing the genes offered by 19 laboratories and vendors, accompanied by annotations. The entire list is available as Cancer Genomics Resource List 2014 as supplemental digital content. A subset of the genes associated with breast cancer and their annotations are included as Table 1. 
